Cargando…

Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort

PURPOSE: We sought to describe clinical and economic outcomes for COPD patients by blood eosinophil (EOS) count. METHODS: This retrospective cohort study of COPD patients used data from the Practice Fusion electronic medical records (EMR) database linked to Symphony Health Solutions transactional ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trudo, Frank, Kallenbach, Lee, Vasey, Joseph, Chung, Yen, Wilk, Alan, Slipski, Lukas, O’Brien, Dan, Strange, Charlie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884975/ https://www.ncbi.nlm.nih.gov/pubmed/32063703 http://dx.doi.org/10.2147/COPD.S220009

Ejemplares similares

Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice
por: Ding, Bo, et al.
Publicado: (2020)

Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population
por: Kern, David M, et al.
Publicado: (2015)

The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
por: Woolley, Michael, et al.
Publicado: (2022)

Burden of disease associated with a COPD eosinophilic phenotype
por: Ortega, Hector, et al.
Publicado: (2018)

Clinical burden of illness among patients with severe eosinophilic COPD
por: Müllerová, Hana, et al.
Publicado: (2019)

Economic Burden of COPD in the Presence of Comorbidities
por: Mannino, David M., et al.
Publicado: (2015)

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
por: Vogelmeier, Claus F., et al.
Publicado: (2019)

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
por: Sandhaus, Robert, et al.
Publicado: (2020)

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
por: Trudo, Frank, et al.
Publicado: (2015)

PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation
por: Tkacz, Joseph, et al.
Publicado: (2022)

Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment
por: Davis, Jill R., et al.
Publicado: (2016)

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
por: Al Ashry, Haitham S., et al.
Publicado: (2017)

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
por: Lal, Chitra, et al.
Publicado: (2016)

Eosinophilic airway inflammation in COPD
por: Saha, Shironjit, et al.
Publicado: (2006)

Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study
por: Kern, David M, et al.
Publicado: (2015)

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
por: Long, Gabriella, et al.
Publicado: (2018)

Economic burden of COPD in a Swedish cohort: the ARCTIC study
por: Lisspers, Karin, et al.
Publicado: (2018)

The association between eosinophilic exacerbation and eosinophilic levels in stable COPD
por: Kang, Hye Seon, et al.
Publicado: (2021)

Blood Eosinophils and Pulmonary Rehabilitation in COPD
por: Aljazeeri, Jafar, et al.
Publicado: (2021)

Algorithm development and the clinical and economic burden of Cushing’s disease in a large US health plan database
por: Burton, Tanya, et al.
Publicado: (2015)

Are blood eosinophils a prime-time biomarker for COPD management decisions?
por: Tsiligianni, Ioanna, et al.
Publicado: (2018)

Economic Burden of COPD by Disease Severity – A Nationwide Cohort Study in Denmark
por: Løkke, Anders, et al.
Publicado: (2021)

Increased hospitalizations and economic burden in COPD with bronchiectasis: a nationwide representative study
por: Kim, Youlim, et al.
Publicado: (2022)

Eosinophils in COPD: why should I care?
por: Fernandes, Frederico Leon Arrabal
Publicado: (2016)

Pulmonary hypertension in eosinophilic versus noneosinophilic COPD
por: Alzghoul, Bashar N., et al.
Publicado: (2021)

Eicosanoids and Eosinophilic Inflammation of Airways in Stable COPD
por: Celejewska-Wójcik, Natalia, et al.
Publicado: (2021)

COPD - Whose Burden, How Large, and What to Do About It?
por: Curtiss, Frederic R.
Publicado: (2005)

Current and projected future economic burden of Parkinson’s disease in the U.S.
por: Yang, Wenya, et al.
Publicado: (2020)

Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population
por: Williams, Setareh A., et al.
Publicado: (2020)

Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma
por: Kolsum, Umme, et al.
Publicado: (2017)

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition
por: Singh, Dave, et al.
Publicado: (2020)

Association between blood eosinophil count and small airway eosinophils in smokers with and without COPD
por: Maetani, Tomoki, et al.
Publicado: (2023)

LB-2. Relative Effectiveness of aIIV3 versus IIV4 and HD-IIV3 In Preventing Influenza-Related Medical Encounters in Adults ≥65 Years of Age at High Risk for Influenza Complications During the U.S. 2017–2018 and 2018–2019 Influenza Seasons
por: Fischer, Lauren, et al.
Publicado: (2020)

The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization
por: Viinanen, Arja, et al.
Publicado: (2019)

Burden of vaccine-preventable diseases among at-risk adult populations in the US
por: Kolobova, Irina, et al.
Publicado: (2022)

Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting
por: Stephenson, Judith J, et al.
Publicado: (2017)

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
por: Iheanacho, Ike, et al.
Publicado: (2020)

Blood eosinophil count as a prognostic biomarker in COPD
por: Oh, Yeon-Mok, et al.
Publicado: (2018)

Blood and sputum eosinophils in COPD; relationship with bacterial load
por: Kolsum, Umme, et al.
Publicado: (2017)

The relationship between airway immunoglobulin activity and eosinophils in COPD
por: Southworth, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_746vhlehef304mk9c4bvfu8oe4